Ci Medical Co., Ltd. (3540) AI Stock Analysis

• Market Cap: ¥50.30B
• Dividend Yield: 1.24%
• Average Volume (3M): 39.20K
• Price to Earnings (P/E): 6.8
• Beta (1Y): 0.93
• Revenue Growth: 67.91%
• EPS Growth: 308.51%
• Country: JP
• Employees: 1,112
• Sector: Consumer Defensive
• Sector Strength: 58
• Industry: Household & Personal Products
• EPS (TTM): 27.35
• Shares Outstanding: 50,000,000
• 10 Day Avg. Volume: 35,800
• 30 Day Avg. Volume: 39,200
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥1,246.00
• Price Target Upside: 23.86% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 75 Outperform
• Price Target: ¥1,100.00 ▲(9.34%Upside)

Ci Medical Co., Ltd. has strong financial performance marked by significant revenue growth and profitability. Valuation metrics are highly favorable, enhancing its investment appeal. However, technical indicators show mixed signals, indicating potential price volatility.

Ci Medical Co., Ltd. Business Overview & Revenue Model

Company Description

Ci Medical Co., Ltd. (3540) is a company that operates within the medical industry, focusing on the development, manufacturing, and distribution of medical devices and equipment. The company specializes in providing innovative healthcare solutions designed to improve patient outcomes and enhance the efficiency of medical procedures. Ci Medical Co., Ltd. is dedicated to advancing healthcare technology by offering a range of products that cater to various medical sectors, including hospitals, clinics, and research institutions.

How the Company Makes Money

Ci Medical Co., Ltd. makes money primarily through the sale of its medical devices and equipment. The company generates revenue by marketing and distributing its products to healthcare providers such as hospitals and clinics. Key revenue streams include direct sales of medical devices, long-term contracts with healthcare institutions, and potentially through partnerships with other medical technology companies that enhance the distribution and development of their products. Additional income streams may come from providing maintenance services for their equipment and offering training programs for medical professionals on the optimal use of their products. Strategic partnerships and collaborations with research institutions may also play a role in expanding their market reach and enhancing their product offerings, contributing to the company's earnings.

Ci Medical Co., Ltd. Financial Statement Overview

Summary

Ci Medical Co., Ltd. shows strong financial performance with significant revenue growth and improved net margins. The balance sheet is stable with effective equity utilization. However, cash flow variability suggests room for operational cash flow stabilization.

Income Statement

Ci Medical Co., Ltd. has shown strong revenue growth over the years, with the 2024 revenue increasing by 47.9% compared to 2023. The company also demonstrates solid profitability, with a consistent gross profit margin around 31.5% in 2024. The net profit margin improved significantly to 9.3% in 2024 from 4.6% in 2023, indicating enhanced efficiency. However, EBIT and EBITDA margins show slight fluctuations, reflecting some variability in operational efficiency.

Balance Sheet

The balance sheet shows a stable financial position with a debt-to-equity ratio of 0.81 in 2024, indicating a conservative leverage approach. The equity ratio remains strong at 41.3%, reflecting a solid capital structure. Return on Equity improved to 24.0% in 2024, showcasing excellent shareholder value creation. However, the increase in total liabilities indicates growing financial obligations.

Cash Flow

Ci Medical Co., Ltd. has a positive free cash flow of ¥4.93 billion in 2024, recovering from negative figures in previous years. The free cash flow to net income ratio is 0.79, suggesting efficient conversion of profits into free cash. However, cash flow from operations shows variability, with significant improvement needed to stabilize the cash generation capability.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	67.49B	45.63B	42.89B	41.20B	37.39B
Gross Profit	21.29B	11.99B	11.67B	11.61B	11.29B
EBITDA	9.48B	4.01B	4.39B	4.87B	4.97B
Net Income	6.27B	2.08B	2.52B	2.82B	2.92B
Balance Sheet
Total Assets	63.17B	41.51B	30.19B	19.91B	18.90B
Cash, Cash Equivalents and Short-Term Investments	4.24B	1.80B	1.83B	3.68B	5.68B
Total Debt	21.21B	17.19B	7.09B	0.00	0.00
Total Liabilities	35.77B	21.37B	11.91B	3.94B	5.14B
Stockholders Equity	26.09B	20.06B	18.22B	15.98B	13.76B
Cash Flow
Free Cash Flow	4.93B	-9.09B	-7.94B	-1.25B	3.70B
Operating Cash Flow	6.15B	-156.00M	1.41B	1.58B	4.16B
Investing Cash Flow	-4.11B	-9.79B	-10.05B	-3.05B	-764.00M
Financing Cash Flow	376.00M	9.82B	6.71B	-584.00M	-150.00M

Ci Medical Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1006.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3540, the sentiment is Positive. The current price of 1006 is above the 20-day moving average (MA) of 977.35, above the 50-day MA of 991.78, and above the 200-day MA of 940.14, indicating a bullish trend. The MACD of 1.16 indicates Negative momentum. The RSI at 56.28 is Neutral, neither overbought nor oversold. The STOCH value of 71.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:3540.

Ci Medical Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3540	75 Outperform	¥50.30B	6.81		1.24%	67.91%	308.51%
4928	74 Outperform	¥159.51B	19.90		4.96%	1.51%	5.48%
4923	73 Outperform	¥42.28B	29.57		1.39%	2.52%	-7.44%
4927	70 Neutral	$286.05B	38.30	4.49%	4.07%	-0.74%	-25.66%
Sector *	68 Neutral	¥216.11B	20.84	8.21%	2.25%	4.80%	-0.56%
4917	67 Neutral	¥65.81B	35.46	2.70%	2.77%	4.03%	-28.60%
4922	61 Neutral	¥333.97B	57.01	2.08%	2.39%	4.63%	-60.17%